Key Highlights

  • Insight Molecular Diagnostics (NASDAQ:IMDX) reported third quarter net Revenue of USD 559,000 against USD 260,000 a year earlier, with one laboratory services customer contributing about USD 538,000 of the total.
  • Net loss narrowed to USD 3.6 million from USD 10.9 million, helped by a USD 4.1 million gain on contingent consideration compared with a USD 3.4 million loss in the prior year quarter.
  • The FDA sent an Additional Information letter on July 25, 2026 about the GraftAssureDx De Novo request, and a complete response is due by January 21, 2027.
  • Cash and cash equivalents were USD 11.0 million at September 30, 2026, after nine-month operating cash use of USD 23.3 million and USD 24.6 million of net proceeds from a February offering.

FDA Letter Puts a January 21, 2027 Deadline on GraftAssureDx

Insight Molecular Diagnostics (NASDAQ:IMDX) filed its Quarterly Report on November 16, 2026 for the period ended September 30. The company submitted a De Novo request for its GraftAssureDx kitted transplant rejection test on March 25, 2026. On July 25 the FDA issued a letter citing deficiencies, mainly in the clinical validation study design and analysis, along with analytical, software and third-party component matters. The FDA's preliminary view is that the data do not yet support the proposed intended use. The request is on hold, and it is treated as withdrawn if a complete response is not received by January 21, 2027.

Smaller Loss Rests on a Contingent Consideration Gain

Third quarter revenue reached USD 559,000, up from USD 260,000, on laboratory services. Cost of revenues rose USD 18,000. Operating costs also rose: sales and Marketing increased USD 221,000 and general and administrative expense USD 240,000, both mostly on stock-based compensation, while Research and Development fell USD 85,000 as professional fees dropped. The net loss of USD 3.6 million compared with USD 10.9 million mainly reflects the contingent consideration line, a USD 4.1 million gain against a USD 3.4 million loss a year earlier, a USD 7.5 million swing by calculation. For nine months, revenue fell to USD 830,000 from USD 2.9 million, and net loss was USD 19.1 million against USD 27.3 million. Management expects laboratory services revenue to be affected as sales staff turn to kitted tests.

USD 11.0 Million of Cash and a Going Concern Evaluation

The company develops molecular test kits that let hospitals and laboratories run transplant rejection testing in-house, built on a digital PCR instrument made by its partner Bio-Rad. It had USD 11.0 million of cash at quarter end and an accumulated Deficit of USD 419.9 million. The February 2026 offering raised USD 26.0 million gross. Management says cash covers at least twelve months, so substantial doubt was not concluded, yet it expects continued operating losses. Shares outstanding were 32,757,434 on November 9, 2026. The company also amended its Chronix Merger earnout terms on September 15.

Where Things Stand

The company says it expects to answer the FDA before the January 21, 2027 deadline, but the filing gives no assurance that the response will resolve the concerns or that the authorization will match the intended use first proposed. Insight Molecular Diagnostics (NASDAQ:IMDX) narrowed its quarterly loss to USD 3.6 million largely through a non-cash gain. Next markers are the complete FDA response, further FDA feedback on its statistical approach and the pace of cash use against USD 11.0 million.